BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Chmielewska-Wilkoń D, Reggiardo G, Egan CG. Otilonium bromide in irritable bowel syndrome: A dose-ranging randomized double-blind placebo-controlled trial. World J Gastroenterol 2014; 20(34): 12283-12291 [PMID: 25232263 DOI: 10.3748/wjg.v20.i34.12283]
URL: https://www.wjgnet.com/1007-9327/full/v20/i34/12283.htm
Number Citing Articles
1
Karin Sandoval, Ken Witt. A worldwide yearly survey of new data in adverse drug reactionsSide Effects of Drugs Annual 2015; 37: 433 doi: 10.1016/bs.seda.2015.05.008
2
Jin-Hyun Lee, Joong Il Kim, Myong Ki Baeg, Yun-Young Sunwoo, Kwangsun Do, Jung-Han Lee, Hye-Jung Kim, Ja Sung Choi, Jayoung Kim, Chang-Seob Seo, Hyeun-Kyoo Shin, Hyekyung Ha, Tae-Yong Park. Effect of Samryungbaekchul-san Combined with Otilonium Bromide on Diarrhea-Predominant Irritable Bowel Syndrome: A Pilot Randomized Controlled TrialJournal of Clinical Medicine 2019; 8(10): 1558 doi: 10.3390/jcm8101558
3
P. Layer, V. Andresen, H. Allescher, S. C. Bischoff, M. Claßen, S. Elsenbruch, M. Freitag, T. Frieling, M. Gebhard, M. Goebel-Stengel, W. Häuser, G. Holtmann, J. Keller, M. E. Kreis, W. Kruis, J. Langhorst, P. Lynen Jansen, A. Madisch, H. Mönnikes, S. Müller-Lissner, B. Niesler, C. Pehl, D. Pohl, M. Raithel, G. Röhrig-Herzog, M. Schemann, S. Schmiedel, J. Schwille-Kiuntke, M. Storr, J. C. Preiß, T. Andus, S. Buderus, U. Ehlert, M. Engel, A. Enninger, W. Fischbach, A. Gillessen, J. Gschossmann, F. Gundling, S. Haag, U. Helwig, S. Hollerbach, M. Karaus, M. Katschinski, H. Krammer, R. Kuhlbusch-Zicklam, H. Matthes, D. Menge, S. Miehlke, M. C. Posovszky, R. Schaefert, A. Schmidt-Choudhury, O. Schwandner, A. Schweinlin, H. Seidl, A. Stengel, J. Tesarz, I. van der Voort, W. Voderholzer, G. von Boyen, J. von Schönfeld, T. Wedel. Update S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie. Gemeinsame Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Neurogastroenterologie und Motilität (DGNM) – Juni 2021 – AWMF-Registriernummer: 021/016Zeitschrift für Gastroenterologie 2021; 59(12): 1323 doi: 10.1055/a-1591-4794
4
Akhilesh Wadhwa, Michael Camilleri, Madhusudan Grover. New and Investigational Agents for Irritable Bowel SyndromeCurrent Gastroenterology Reports 2015; 17(12) doi: 10.1007/s11894-015-0473-x
5
Kwang Jae Lee. Pharmacologic Agents for Chronic DiarrheaIntestinal Research 2015; 13(4): 306 doi: 10.5217/ir.2015.13.4.306
6
Pere Clavé, Jan Tack. Efficacy of otilonium bromide in irritable bowel syndrome: a pooled analysisTherapeutic Advances in Gastroenterology 2017; 10(3): 311 doi: 10.1177/1756283X16681708
7
Ruijie Li, Fuping Chen, Xuanxuan He, Yuqing Feng, Qiaoqiao Pei, Dongke Wang, Xinghuang Liu, Jinsong Liu, Xiaohua Hou, Tao Bai. Nocebo response intensity and influencing factors in the randomized clinical trials of irritable bowel syndrome: A systematic review and meta-analysisFrontiers in Medicine 2022; 9 doi: 10.3389/fmed.2022.1018713
8
Darren M. Brenner, Brian E. Lacy. Antispasmodics for Chronic Abdominal Pain: Analysis of North American Treatment OptionsAmerican Journal of Gastroenterology 2021; 116(8): 1587 doi: 10.14309/ajg.0000000000001266
9
Kai-Yue Huang, Feng-Yun Wang, Mi Lv, Xiang-Xue Ma, Xu-Dong Tang, Lin Lv. Irritable bowel syndrome: Epidemiology, overlap disorders, pathophysiology and treatmentWorld Journal of Gastroenterology 2023; 29(26): 4120-4135 doi: 10.3748/wjg.v29.i26.4120